Molbio Diagnostics Reports Rs 52.7 Cr Profit in Q1 Post-IPO

Molbio Diagnostics, a recent entrant to the stock market, has announced a significant financial turnaround with a profit of Rs 52.74 crore for the first quarter ending June 2026. This marks a stark contrast to the Rs 23.94 crore loss recorded in the same period last year. The company attributes this positive shift to the robust sales of its flagship product, the Truenat test-kit.

Successful IPO and Revenue Growth

The diagnostics firm recently raised approximately Rs 940 crore through its Initial Public Offering (IPO), which saw the company being listed on the bourses on August 17. Following this successful IPO, Molbio Diagnostics reported a total income of Rs 411.48 crore in the first quarter of the current fiscal year, compared to Rs 100.47 crore in Q1 FY26. This substantial increase is credited to the rising demand for its Truenat test-kits.

Truenat Test-Kit Demand Surges

Truenat test-kit sales have been a major contributor to the company’s financial performance, with volumes soaring to 62.4 lakh units, a significant jump from 7,90,000 units during the previous year’s corresponding quarter. The Truenat test-kit is designed to detect a wide array of infectious diseases quickly and accurately at the point of care, positioning it as a vital tool in the diagnostics industry.

Leadership's Optimistic Outlook

Sriram Natarajan, Executive Director and CEO of Molbio Diagnostics, expressed optimism about the company's trajectory, stating, "FY27 is a milestone year for Molbio, marking our transition to a listed company. We have begun the year on a strong note, with healthy growth across both revenue and profitability in Q1." This statement highlights the leadership’s confidence in sustaining the company's growth momentum.

The impressive Q1 financial results underscore the impact of strategic product offerings and successful market entry through the IPO. As Molbio Diagnostics continues to expand its footprint, the focus remains on leveraging the Truenat test-kit’s growing popularity to drive further growth in the diagnostics sector.